ClinicalTrials.gg
CompletedNCT00077584RAPIDS-2Updated Feb 3, 2025

Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma

A Phase 3 interventional study of Bosentan 62.5 mg and Bosentan 125 mg in Digital Ulcers and Systemic Sclerosis, sponsored by Actelion. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In an earlier clinical trial, RAPIDS-1, conducted in scleroderma patients with or without digital ulcers at baseline, bosentan significantly reduced the number of new digital ulcers versus placebo. The purpose of the present trial (RAPIDS-2) is to evaluate the prevention and healing effects of bosentan versus placebo on digital ulcers over a 24-week treatment period.

02

Conditions studied

  • Digital Ulcers
  • Systemic Sclerosis

Keywords

  • Scleroderma
  • Finger Ulcers
  • Digital Ulcers
  • Systemic Sclerosis
03

In context

digital ulcers

29 studies on the registry are indexed under digital ulcers; 7 are open to participants now.

This study's enrollment of 188 is above the median of 40 across 23 interventional studies indexed under digital ulcers.

Browse digital ulcers studies →

Lead sponsor

Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.

First submitted before Actelion became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Systemic Sclerosis (SSc), diffuse or limited.
  • SSc patients with at least one digital ulcer at baseline qualifying as a cardinal ulcer.

Main Exclusion Criteria:

  • Digital ulcers due to conditions other than SSc.
  • Severe pulmonary arterial hypertension (PAH) (Who class III and IV).
  • Malabsorption or any severe organ failure (e.g., lung, kidney, liver) or any life-threatening condition.
  • Treatment with parenteral prostanoids (prostaglandin E, epoprostenol, or prostacyclin analogs) during the past 3 months prior to randomization.
  • Treatment with inhaled or oral prostanoids one month prior to randomization.
  • Previous treatment with bosentan.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    Bosentan

    The patients received bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks and then 125 mg b.i.d. for 20 weeks

    Drug: Bosentan 62.5 mg · Drug: Bosentan 125 mg

  • Placebo comparator
    Placebo

    The patients received the matching placebo for 24 weeks

    Drug: Placebo

Interventions

  • Oral tablets containing 62.5 mg of bosentan

    Also known as: Ro 47-0203

  • Oral tablets containing 125 mg of bosentan

    Also known as: Ro 47-0203

  • DrugPlacebo

    Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets

06

What researchers measure

Primary outcomes

  1. Time to complete healing of the cardinal ulcer (CU) up to Week 24 in patients with CU healing maintained for 12 weeks

    Time frame: 24 weeks

  2. Total number of new digital ulcers per patient up to Week 24

    Time frame: 24 weeks

Secondary outcomes

  1. Change from baseline to Week 24 in hand pain

    Pain assessed on visual analog scales

    Time frame: Baseline and Week 24

  2. Change from baseline to Week 24 in hand disability

    Hand disability indexed assessed using the Health Assessment Questionaire (HAQ)

    Time frame: Baseline and Week 24

  3. Proportion of subjects with treatment-emergent adverse events

    Time frame: up to 32 weeks (8 week post-treatment follow-up)

  4. Proportion of subjects with liver function abnormalities

    Increase in aminotransferases

    Time frame: Every 4 weeks up to Week 24

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA Jr, Morganti A, Kramer F, Korn JH, Seibold JR. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011 Jan;70(1):32-8. doi: 10.1136/ard.2010.130658. Epub 2010 Aug 30. PubMed 20805294 ↗
  • Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev. 2021 Mar 26;3(3):CD004434. doi: 10.1002/14651858.CD004434.pub6. PubMed 33765691 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2003, a primary completion of Mar 2005 and a completion of May 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2004
First posted
Feb 11, 2004
Start
Oct 2003
Primary completionActual
Mar 2005
CompletionActual
May 2005
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00077584
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Feb 11, 2004
Start date
Oct 2003
Primary completion
Mar 2005
Completion
May 2005
Last update
Feb 3, 2025

Study contacts

James Seibold, MD
principal investigator · Robert Wood Johnson Medical School, New Brunswick, NJ, USA
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bosentan

Start the discussion